Featured Studies

Healthy volunteers 18-60 years old are needed to test an investigational drug that was developed to reduce blood pressure in the lungs. The PAH team from @NHLBI hope that this investigational study drug may be helpful in treating patients with PAH in the future.

Researchers are examining genetic and physical characteristics of the small vessel disease called CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy). They are enrolling volunteers to serve as healthy controls. Compensation is provided.

Pharmacologic therapy with Bruton's tyrosine kinase (BTK) inhibitors is associated with an increased risk of heart problems like atrial fibrillation, bleeding, and high blood pressure (hypertension) which can lead to sudden death. There is currently no standard for cardiac screening or monitoring patients on BTK inhibitors. Researchers at the National Heart, Lung, and Blood Institute (NHLBI) are investigating the relationship between the development of heart problems in patients on BTKi as it relates to other variables.

The research study aims to enhance the understanding of SCD and its associated complications by investigating the relationship between the disease and specific variations of certain genes. If you have SCD, your participation in this study is highly valuable. By participating, you will undergo an evaluation and receive recommendations from a team experienced in the treatment and management of SCD.

Systemic lupus erythematosus (SLE) creates an imbalance in the innate immune system responsible for chronic inflammation. A study at NHLBI is looking into a Vitamin B supplement, nicotinamide riboside (NR), to see if it improves immune system function in people with SLE. People with SLE will be asked to take the supplement or placebo for 12 weeks. Healthy control subjects will be enrolled to compare baseline blood results but will not take the supplement.